Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 26;16(6):791. doi: 10.3390/ph16060791

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the author.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Results from clinical evaluation of OMDI (0.002%; once daily topical ocular dosing) in a variety of patients afflicted with different types of glaucomas are displayed. The data show that OMDI exhibited different levels of ocular hypotensive activity in these varied populations of glaucoma patients. Apparently, OMDI lowered the highest magnitude of IOP in patients with OHT and secondary forms of glaucoma and exerted slightly lower efficacy in a group of OAG/NTG and ACG patients. Nevertheless, OMDI is an effective ocular hypotensive medication that is well tolerated and is effective in all four types of glaucoma/OHT patients after 4 and 12 weeks of treatment. Asterisk denotes statistically significant verses the baseline values.